⌘K
Loading ticker…
As of 2026-08-21, Turn Therapeutics Inc. Common Stock (TTRX) has a 3-month relative strength percentile of 97 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.7%, relative volume 0.39×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Not enough history to compute monthly seasonality for TTRX.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
TTRX appears in 1 ETF as of Mar 2026: VTI at 0.00% weight, $108K notional.
Held by 1 ETFs · $108K across latest filings · largest weight 0.00% (VTI).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $108K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News